Home  »  Business   »  Can Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) S...

Can Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Still Be Hot This Week?

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded at $14.76 at close of the session on Monday, 01/23/23, made a downward move of -29.04% on its previous day’s price.

Looking at the stock we see that its previous close was $20.80 and the beta (5Y monthly) reads 1.29 with the day’s price range being $13.30 – $18.41. The company has a trailing 12-month PE ratio of 24.28. In terms of its 52-week price range, CPRX has a high of $22.11 and a low of $5.24. The company’s stock has lost about -20.65% over that past 30 days.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Catalyst Pharmaceuticals Inc. has a market cap of $1.50 billion and is expected to release its quarterly earnings report on Mar 14, 2023 – Mar 20, 2023. Estimates by analysts give the company expected earnings per share (EPS) of $0.19, with the EPS growth for the year raised at $0.7 for 2022 and $0.85 for next year. These figures represent 89.20% and 21.40% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $53.62 million, with a low of $53.26 million and a high of $54.24 million. The median projection represents growth squeezing down to 55.00% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $205.03 million, or 45.60% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CPRX stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 50% Buy.

Based on estimates by 5 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Catalyst Pharmaceuticals Inc. (CPRX) stock as a Hold, while 4 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -24.07% off its SMA20 and -16.25% from its 50-day simple moving average. The RSI (14) is pointing at 33.14 while the volatility over the past week is 11.49% and jumps to 7.14% over the past one month. The beta value is 1.26, while the average true range (ATR) is currently pointing at 1.53. The average price target for the stock over the next 12 months is $20.70, with the estimates having a low of $15.50 and a high of $24.00. These price ends are -5.01% and -62.6% off the current price level respectively, although investors could be excited at the prospect of a -49.05% if the CPRX share price touches on the median price of $22.00.

Let’s briefly compare Catalyst Pharmaceuticals Inc. (CPRX) stock to its peers. We find that current price change of -29.04% and 159.40% over the past 12 months for CPRX competes that of Johnson & Johnson (JNJ), which has seen its stock price fall -0.25% in the last trading session and was 1.85% over the last one year. Another of its peers Pfizer Inc. (PFE) has dropped -0.29% previous session, and was -16.78% down over the past year, while Abbott Laboratories (ABT) was also up 1.05% in the last session, while its price remained in the red at -8.58% over the same period. Catalyst Pharmaceuticals Inc. has a P/E ratio of 24.28 compared to Johnson & Johnson’s 23.43 and Pfizer Inc.’s 8.53. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.19% and 0.76%, respectively, at close of the trading.

Coming back to Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), we note that the average 3-month trading volume was 2.35 million, while that of the preceding 10-day period stands at 3.81 million. Current shares outstanding are 103.32 million.

The insiders hold 5.90% of the company’s shares while institutions hold 83.20%. The data shows that short shares as of Oct 13, 2022, stood at 8.72 million at a short ratio of 2.18. This represents a 8.48% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 4.97 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -20.65% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

5 Lithium Stocks with High Future Potential

Demand for lithium is expected to increase 8-fold by 2030. The world's largest automakers are racing to go green as the global EV boom continues.


We have collated a list of top five lithium stocks which are well positioned to benefit from the 2023 lithium boom because of their focus on multiple high-potential lithium projects.

100% free. stop anytime no spam